Is Glaukos Corp (GKOS) overvalued? · rev $383.5M
Glaukos Corp (GKOS) is a medical devices company listed on NYSE.
This page asks whether Glaukos Corp (GKOS) looks expensive on cached numbers — not a short thesis.
Latest reported GKOS revenue for 2024-12-31 was $383.5M. Net income was -$146.4M. Revenue was up 21.9% from 2023-12-31 to 2024-12-31. GKOS currently screens at market cap $7.63B.
GKOS currently screens at market cap $7.63B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GKOS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GKOS stock page for the full model, not this heading.
Not investment advice.